Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin J Freise

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
European Journal of Clinical Pharmacology|January 6, 2018
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokineticsKevin J Freise, Beibei Hu, Ahmed Hamed Salem
Journal of Clinical Pharmacology|January 5, 2017
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelKevin J Freise, Mohamad Shebley, Ahmed Hamed Salem
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2009
Erythropoietic response to endogenous erythropoietin in premature very low birth weight infantsKevin J Freise, John A Widness, Peter Veng-Pedersen
Clinical and Translational Science|January 22, 2020
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and DigoxinAli A Alhadab, Ahmed Hamed Salem, Kevin J Freise
Medicine|September 1, 2017
Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patientsMengyao Li, Nimita Dave, Ahmed Hamed Salem, et al.
Hematological Oncology|April 20, 2018
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trialsNaveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 23, 2007
Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheepKevin J Freise, John A Widness, Robert L Schmidt, et al.
The Journal of Pharmacy and Pharmacology|September 25, 2008
Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietinPeter Veng-Pedersen, Kevin J Freise, Robert L Schmidt, et al.
Hematological Oncology|July 15, 2017
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trialsNaveen Mangal, Ahmed Hamed Salem, Mengyao Li, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
European Journal of Clinical Pharmacology|January 6, 2018
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokineticsKevin J Freise, Beibei Hu, Ahmed Hamed Salem
Journal of Clinical Pharmacology|January 5, 2017
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic ModelKevin J Freise, Mohamad Shebley, Ahmed Hamed Salem
CPT: Pharmacometrics & Systems Pharmacology|January 20, 2019
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure-Response Analyses Underutilized?Aksana K Jones, Ahmed Hamed Salem, Kevin J Freise
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2009
Erythropoietic response to endogenous erythropoietin in premature very low birth weight infantsKevin J Freise, John A Widness, Peter Veng-Pedersen
Clinical and Translational Science|January 22, 2020
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and DigoxinAli A Alhadab, Ahmed Hamed Salem, Kevin J Freise
Medicine|September 1, 2017
Model-based meta-analysis of progression-free survival in non-Hodgkin lymphoma patientsMengyao Li, Nimita Dave, Ahmed Hamed Salem, et al.
Hematological Oncology|April 20, 2018
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trialsNaveen Mangal, Ahmed Hamed Salem, Rajeev M Menon, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 23, 2007
Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheepKevin J Freise, John A Widness, Robert L Schmidt, et al.
The Journal of Pharmacy and Pharmacology|September 25, 2008
Pharmacokinetic differentiation of drug candidates using system analysis and physiological-based modelling. Comparison of C.E.R.A. and erythropoietinPeter Veng-Pedersen, Kevin J Freise, Robert L Schmidt, et al.
Hematological Oncology|July 15, 2017
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trialsNaveen Mangal, Ahmed Hamed Salem, Mengyao Li, et al.
Pageof 4